You are here

Retrophin

Retrophin no more: Shkreli's legacy disappears as former company becomes Travere Therapeutics

Retrophin no more: Shkreli's legacy disappears as former company becomes Travere Therapeutics

Endpoints

Travere Therapeutics

Flag link:

Retrophin to buy Orphan Tech for $90M upfront

Retrophin to buy Orphan Tech for $90M upfront

Seeking Alpha

enzyme replacement

Flag link:

Top 7 Companies in Biotech Beach by Revenue

Top 7 Companies in Biotech Beach by Revenue

BioSpace

Acadia Pharmaceuticals

Mirati Therapeutics

Flag link:

Retrophin Sinks as Drug “Pharma Bro” Martin Shkreli Co-Invented Fails

Retrophin Sinks as Drug “Pharma Bro” Martin Shkreli Co-Invented Fails

Xconomy

fosmetpantotenate

Flag link:

Retrophin paid Martin Shkreli 'undisclosed sum' to settle yearslong legal disputes

Retrophin paid Martin Shkreli 'undisclosed sum' to settle yearslong legal disputes

Endpoints

Flag link:

FDA Approves Retrophin’s New Formula for Cystine Kidney Stones

FDA Approves Retrophin’s New Formula for Cystine Kidney Stones

BioSpace

cystine kidney stones

Flag link:

The Week Ahead In Biotech: Pending Clinical Readouts In Focus

The Week Ahead In Biotech: Pending Clinical Readouts In Focus

Yahoo/Benzinga

Sangamo Therapeutics

Catalyst Biosciences

Reata Pharmaceuticals

Vertex Pharmaceuticals

Gilead Sciences

TRACON Pharmaceuticals

Sorrento Therapeutics

Flag link:

FDA Action Alert: Regeneron, Sanofi, Celgene

FDA Action Alert: Regeneron, Sanofi, Celgene

BioSpace

Acer Therapeutics

Dova Pharmaceuticals

Nabriva Therapeutics

Flag link:

After years of claims and accusations, fraudster Martin Shkreli settles up with Retrophin

After years of claims and accusations, fraudster Martin Shkreli settles up with Retrophin

Endpoints

Flag link:

Shkreli settles into his new prison digs in Pennsylvania with a $30M+ lawsuit against former Retrophin colleagues

Shkreli settles into his new prison digs in Pennsylvania with a $30M+ lawsuit against former Retrophin colleagues

Endpoints

Flag link:

Go or no go? Merck, Regeneron and Alexion await US expansion

Go or no go? Merck, Regeneron and Alexion await US expansion

EP Vantage

Dova Pharmaceuticals

Flag link:

Made for TV: Shkreli running his drug company from prison cell, WSJ says

Made for TV: Shkreli running his drug company from prison cell, WSJ says

Fierce Pharma

Flag link:

Deflating R&D claims, prosecutors say an impatient Martin Shkreli conducted bogus drug study in Cyprus

Deflating R&D claims, prosecutors say an impatient Martin Shkreli conducted bogus drug study in Cyprus

Endpoints

clinical trials

Flag link:

From ‘Rain Man’ to ‘Pied Piper,’ Shkreli's actions confounded Retrophin executives

From ‘Rain Man’ to ‘Pied Piper,’ Shkreli's actions confounded Retrophin executives

Fierce Pharma

Flag link:

Feds’ case spotlights Shkreli’s disastrous biotech short — which forced him to launch Retrophin

Feds’ case spotlights Shkreli’s disastrous biotech short — which forced him to launch Retrophin

Endpoints

Flag link:

Martin Shkreli’s former biotech company Retrophin is leaving Cambridge

Martin Shkreli’s former biotech company Retrophin is leaving Cambridge

Bizjournals.com

Flag link:

Martin Shkreli in court as securities fraud case moves closer to trial

Martin Shkreli in court as securities fraud case moves closer to trial

CNBC

securities fraud

Flag link:

4 Key BioPharma Movers in the Past Week

4 Key BioPharma Movers in the Past Week

24/7 Wall St

Lexicon Pharmaceuticals

Flag link:

Retrophin (With Help From Martin Shkreli) Advances Drug for Rare Kidney Disease

Retrophin (With Help From Martin Shkreli) Advances Drug for Rare Kidney Disease

TheStreet.com

focal segmental glomerulosclerosis

Flag link:

Pages